main content start

Pagina inicial 1

Continue Watching

Últimos vídeos

Últimos vídeos

Brightcove Home Latest Listing

Câncer de mama

Câncer de próstata

Câncer de próstata

Brightcove Cards Listing

Mieloma múltiplo

Mieloma múltiplo

Brightcove Cards Listing

Popular em MedEnrich

Popular em MedEnrich

Popular in Sem nome
  • Mieloma múltiplo6m 23s

    Bone Targeted Treatments in Multiple Myeloma 2024-03-VD-EM-MMY-07

    Long-term usage of bisphosphonates should be balanced with the potential of possible side-effects. Watch the detailed video on MedEnrich to learn about use of bone targeted agents, its dosage, frequency, optimal usage and limitations.
    bisphosphonates convenient agent bone lesions side-effects
  • Mieloma múltiplo4m 12s

    Key Practice Points -Myeloma Related Renal Impairment

    In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
    myeloma renal impairment key practice points
  • Myelodysplastic Syndromes7m 3s

    Clinical Application of Web Based Tool for Improving MDS Diagnosis

    Gradient Based Model based on 10 routinely used parameters (Age, Gender, Hb, WBC, MCV, Platelets, Neutrophils, Monocytes, Glucose, Creatinine) is now available to facilitate non-invasive diagnosis of MDS.
    mds non-invasive diagnosis
  • Mieloma múltiplo7m 22s

    Using Bone Targeted Therapy in Special Situations in Multiple Myeloma

    Bone targeting agents have different toxicities and rare complications which are dependent on the exposure to the specific treatment. Watch detailed video on MedEnrich on use of bone targeted agent in Multiple Myeloma
    bisphosphonates renal insufficiency hypercalcemia
  • 11m 43s

    Sequencing of treatment for Her2 positive MBC in 2022

    Noteworthy treatment options added in the treatment guidelines for Her2 positive MBC are Trastuzumab Deruxtecan (TDXd) and combination of Trastuzumab + Capecitabine +Tucatinib.
    brain metastases her2 positive mbc trastuzumab deruxtecan tucatinib
  • 11m 43s

    Sequencing of treatment for Her2 positive MBC in 2022

    Noteworthy treatment options added in the treatment guidelines for Her2 positive MBC are Trastuzumab Deruxtecan (TDXd) and combination of Trastuzumab + Capecitabine +Tucatinib.
    brain metastases her2 positive mbc trastuzumab deruxtecan tucatinib
  • Myelodysplastic Syndromes8m 45s

    Current Challenges in MDS Diagnosis and Consequences

    Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
    non invasive mds diagnosis web based mds diagnosis tools
  • Câncer de próstata6m 1s

    Androgen Receptor Targeted Therapies in patients with Cardiovascular Co Morbidities

    Referring the patients to cardiologist is an important aspect of managing patients with cardiovascular co-morbidities.
    hypertension cardiac events cardiovascular co-morbidities
  • Mieloma múltiplo8m 23s

    Treatment of High Risk Myeloma Patients

    While treating high risk patients it is critical to address complex biology & maximize the response for individual patients by gaining depth of response & maintaining that response for long duration. To ensure good quality of life patients should hav
    high risk myeloma
  • Critical Care24m 59s

    Atualizações no tratamento de de infecções SNC por Enterecoccus faecium

    Atualizações e Considerações no tatamento de infecções SNC por Enterecoccus faecium resistentes à Vancomicina
    infecções hospitalares hospitalar daptomicina resistência à vancomicina terapia antimicrobiana
  • Webinar passado

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hola, ¿puedo ayudar?
    Suporte por bate-papoX
    Equipe de suporte
    Hola, ¿cómo puedo ayudarlo hoy?
    Seleccione una de las siguientes opciones.

    Buscar información

    No puedo iniciar sesión o registrarse

    compartilhar comentarios